ALX Oncology Holdings Inc. (ALXO) Earnings History
Annual and quarterly earnings data from 2018 to 2024
Loading earnings history...
ALXO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ALXO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | 9.1% | -3694.0% | -3869.7% |
Download Data
Export ALXO earnings history in CSV or JSON format
Free sign-in required to download data
ALX Oncology Holdings Inc. (ALXO) Earnings Overview
As of May 6, 2026, ALX Oncology Holdings Inc. (ALXO) reported trailing twelve-month net income of -$108M, reflecting +31.0% year-over-year growth. The company earned $-2.02 per diluted share over the past four quarters.
Looking at the long-term picture, ALXO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2018.
ALX Oncology Holdings Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$136M net income, -2051.1% margin), IMVT (-$464M net income), RCUS (-$369M net income, -142.9% margin), ALXO has comparable earnings metrics. Compare ALXO vs FATE →
ALXO Earnings vs Peers
Earnings metrics vs comparable public companies
ALXO Historical Earnings Data (2018–2024)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$135M | +16.1% | -$142M | $-2.58 | - | - |
| 2023 | -$161M | -30.2% | -$170M | $-3.74 | - | - |
| 2022 | -$123M | -47.9% | -$127M | $-3.03 | - | - |
| 2021 | -$83M | -82.5% | -$84M | $-2.07 | - | - |
| 2020 | -$46M | -137.7% | -$44M | $-1.28 | -3869.7% | -3694.0% |
| 2019 | -$19M | -40.1% | -$19M | $-0.88 | -401.2% | -400.0% |
| 2018 | -$14M | - | -$14M | $-0.63 | -664.3% | -662.0% |
See ALXO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALXO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALXO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALXO — Frequently Asked Questions
Quick answers to the most common questions about buying ALXO stock.
Is ALXO growing earnings?
ALXO EPS is $-2.02, with earnings growth accelerating to +31.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-108M.
What are ALXO's profit margins?
ALX Oncology Holdings Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ALXO's earnings?
ALXO earnings data spans 2018-2024. The accelerating earnings trend is +31.0% YoY. Historical data enables comparison across business cycles.